

The Alpha-1 Study

Antitrypsin Deficiency-Related Liver Disease Treatment Using Carbamazepine

A preliminary study of the efficacy and safety of carbamazepine in severe liver disease due to alpha-1 antitrypsin deficiency

A National Institutes of Health Sponsored Research Study

Can carbamazepine (CBZ) reduce the severity of liver disease that occurs in people with alpha-1 antitrypsin deficiency (ATD)?

BACKGROUND:

- ATD is a genetic disorder that can lead to liver fibrosis/ cirrhosis and respiratory problems.
- There is presently no cure.
- Study evaluates the effects and effectiveness of CBZ over a 12-month period.

ELIGIBILITY:

Patient must:

- Have ATD (either ZZ or SZ type)
- Be between 14 and 80 years of age
- Meet other eligibility requirements

Find more information online at
www.chp.edu/liverstudy

CONTACT INFORMATION:

David H. Perlmutter, MD
Primary Investigator
1-855-428-2281
liverstudy@chp.edu

